Get started
Author

Antje Karen Kretzschmar

Interleukin-6–dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer
2007 · Dennis Löffler, Katja Brocke-Heidrich, et al. · Blood · 649
PDF
MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma
2012 · K Boll, K Reiche, et al. · Oncogene · 217
TFAP2E–DKK4 and Chemoresistance in Colorectal Cancer
2012 · Matthias P.A. Ebert, Marc Tänzer, et al. · New England Journal of Medicine · 193
PDF
Interleukin-6–dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family–independent survival pathway closely associated with Stat3 activation
2003 · Katja Brocke-Heidrich, Antje K. Kretzschmar, et al. · Blood · 152
PDF
Homodimerization of Neuropeptide Y Receptors Investigated by Fluorescence Resonance Energy Transfer in Living Cells
2003 · Michaela C. Dinger, Jürgen E. Bader, et al. · Journal of Biological Chemistry · 134
Analysis of Stat3 (signal transducer and activator of transcription 3) dimerization by fluorescence resonance energy transfer in living cells
2004 · Antje K. KRETZSCHMAR, Michaela C. DINGER, et al. · Biochemical Journal · 114
PDF
Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity
1998 · C-H Köhne, P Thuss-Patience, et al. · British Journal of Cancer · 65
PDF
Cyclophilins contribute to Stat3 signaling and survival of multiple myeloma cells
2009 · K Bauer, A K Kretzschmar, et al. · Oncogene · 62
Differential Membrane Proteome Analysis Reveals Novel Proteins Involved in the Degradation of Aromatic Compounds in Geobacter metallireducens
2009 · Dimitri Heintz, Sébastien Gallien, et al. · Molecular & Cellular Proteomics · 34
PDF
1429P Pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: Results from the DANTE trial of the German Gastric Group at the AIO and SAKK
2021 · S-E. Al-Batran, S. Lorenzen, et al. · Annals of Oncology · 32
1421MO Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma
2020 · S-E. Al-Batran, G.M. Haag, et al. · Annals of Oncology · 27
PDF
Oral Trofosfamide: An Active and Well-Tolerated Maintenance Therapy for Adult Patients with Advanced Bone and Soft Tissue Sarcomas. Results of a Retrospective Analysis
2002 · P. Reichardt, D. Pink, et al. · Oncology Research and Treatment · 23
Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial
2022 · L. Weiss, M. Karthaus, et al. · ESMO Open · 18
First-Line Chemotherapy for Colorectal Carcinoma – We are Making Progress
1998 · C.H. Köhne, A. Kretzschmar, et al. · Oncology Research and Treatment · 18
Incidence of bone metastases in GIST: A single center analysis of 307 patients with metastatic disease
2008 · M. Schuler, M. Zeile, et al. · Journal of Clinical Oncology · 12
Feasibility of metastasectomy in patients treated with bevacizumab in first-line mCRC - Preliminary results from the First Beat-study
2006 · M. Michael, E. Vancutsem, et al. · Journal of Clinical Oncology · 12
6088 Safety and efficacy of bevacizumab (BEV) and chemotherapy in elderly patients with metastatic colorectal cancer (mCRC): results from the BEAT observational cohort study
2009 · E. Van Cutsem, F. Rivera, et al. · European Journal of Cancer Supplements · 10
A randomized, phase IIb study of sunitinib plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) versus bevacizumab plus mFOLFOX6 as first-line treatment for metastatic colorectal cancer (mCRC): Interim results.
2010 · J. R. Hecht, T. Yoshino, et al. · Journal of Clinical Oncology · 9
Co-activator SRC-1 is dispensable for transcriptional control by STAT3
2009 · Helena Cvijic, Kay Bauer, et al. · Biochemical Journal · 8
PDF
1494P Updated safety data of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma - A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK
2020 · S-E. Al-Batran, S. Lorenzen, et al. · Annals of Oncology · 7
PDF
Zoledronic acid (Z) as palliative treatment in cancer patients with bone metastases: Interim results of a prospective, open-label trial
2004 · A. Kretzschmar, T. Wiegel, et al. · Journal of Clinical Oncology · 3
1430P Frequency of PD-L1 positivity and microsatellite instability (MSI) in the DANTE trial: Perioperative atezolizumab with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma. A randomized, open-label phase IIb trial of the German gastric group at the AIO and SAKK
2021 · C. Kopp, S. Lorenzen, et al. · Annals of Oncology · 2
PDF
Epirubicin Weekly in Combination Chemotherapy with Cyclophosphamide and Vincristin in Untreated Small Cell Lung Cancer: A Phase II Trial
2009 · A. Kretzschmar, P. Drings · Onkologie · 2
Eine neue hoch effektive Therapie der indolenten Non-Hodgkin-Lymphome mit Bendamustin
2003 · P.C. Thuss-Patience, A. Kretzschmar, et al. · Oncology Research and Treatment · 2
PDF
6th International Consensus Conference on the Treatment of Primary Breast Cancer
1998 · C.H. Köhne, A. Kretzschmar, et al. · Oncology Research and Treatment · 2
PDF
Works count: 37
Citation count: 1,808
H-index: 14
I10-index: 17
Year
Topic
Type